Targeting Leukemia by Blocking a Protein Process
Project 3: Therapeutic inhibition of splicing through inhibition of protein arginine methylation in leukemia
['FUNDING_OTHER'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11124246
This research looks for new ways to stop leukemia cells from growing by blocking specific protein changes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11124246 on ClinicalTrials.gov |
What this research studies
Leukemia cells often have genetic changes that affect how their genes work, and researchers found that both myeloid and lymphoid leukemia cells depend on a group of enzymes called PRMTs to survive. Blocking these PRMT enzymes seems to disrupt how RNA is processed, which is crucial for cell function. This approach has shown promise in killing leukemia cells, especially those with certain genetic mutations, and combining different blocking methods might be even more effective. The goal is to understand how PRMT inhibitors work and find markers to predict which patients will respond best to these treatments.
Who could benefit from this research
Good fit: Patients with acute myeloid leukemia (AML) or other lymphoid leukemias, particularly those with specific spliceosomal mutations, might be ideal candidates for future treatments based on this research.
Not a fit: Patients whose leukemia cells do not rely on these specific protein changes or who do not have the identified genetic mutations may not benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatments for patients with acute myeloid and lymphoid leukemias, especially those with specific genetic mutations.
How similar studies have performed: Prior studies have identified PRMT5 as a promising target in cancer, with a PRMT5 inhibitor currently in a Phase I clinical trial for other cancers, suggesting a foundation for this approach.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABDEL-WAHAB, OMAR — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: ABDEL-WAHAB, OMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers